Theravance Biopharma, Inc.
TBPH
$14.30
$0.130.92%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 70.23% | -17.95% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 70.23% | -17.95% | |||
| Cost of Revenue | -8.40% | 21.15% | |||
| Gross Profit | 299.01% | -57.68% | |||
| SG&A Expenses | 0.33% | -0.71% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.02% | 6.68% | |||
| Operating Income | 81.12% | -56.89% | |||
| Income Before Tax | 617.80% | -58.16% | |||
| Income Tax Expenses | 3,386.40% | -108.49% | |||
| Earnings from Continuing Operations | 503.82% | 12.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 503.82% | 12.55% | |||
| EBIT | 81.12% | -56.89% | |||
| EBITDA | 83.48% | -59.73% | |||
| EPS Basic | 500.00% | 13.24% | |||
| Normalized Basic EPS | 612.82% | -56.93% | |||
| EPS Diluted | 495.31% | 13.24% | |||
| Normalized Diluted EPS | 607.31% | -56.93% | |||
| Average Basic Shares Outstanding | 0.95% | 0.81% | |||
| Average Diluted Shares Outstanding | 2.05% | 0.81% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||